Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...
Sanofi's amlitelimab confirms its potential in atopic dermatitis: Paris Saturday, January 24, 2026, 10:00 Hrs [IST] Following the positive COAST 1 (clinical study identifier: NCT0 ...
Everyday Health on MSN
15 burning questions about Ozempic, answered
Explore the benefits and side effects of popular weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. Learn how ...
SHORE study In the SHORE study, amlitelimab, dosed either Q4W or Q12W in conjunction with medium-potency background topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results